Jacinta L. Simmons
Brisbane, QLD, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: March 31, 2024
Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.
Journal: Frontiers in cell and developmental biology
Published: March 10, 2023
Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice.
Journal: Experimental hematology & oncology
Published: October 06, 2022
Anti-Fibrotic Potential of Tomentosenol A, a Constituent of Cerumen from the Australian Native Stingless Bee, Tetragonula carbonaria.
Journal: Antioxidants (Basel, Switzerland)
Published: June 13, 2022
Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes.
Journal: Scientific reports
Published: September 04, 2020
BRN2 and MITF together impact AXL expression in melanoma.
Journal: Experimental dermatology
Published: July 27, 2020
Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.
Journal: The Journal of investigative dermatology
Published: July 10, 2020
BRN2 expression increases anoikis resistance in melanoma.
Journal: Oncogenesis
Published: January 07, 2020
MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.
Journal: Scientific reports
Published: January 16, 2017
Last Updated: 09/26/2026